Nanodiamond-Based Anti-HIV Drug Delivery


IP 1617-Therapeutic efficacy of ND-EFV on HIV-1 infected Macrophages

Florida International University (FIU) is seeking a business partner to develop and commercialize Compositions and Methods for Treating Human Immunodeficiency Virus (HIV) by targeting HIV reservoir organs using nanodiamond (ND) particles loaded with Efavirenz.

Human immunodeficiency virus type 1 (HIV-1) remains one of the leading causes of death worldwide, principally in developing countries. Although therapeutic agents exist for the treatment of HIV-AIDS, drug-induced toxicities and pharmacokinetic limitations commonly result in poor compliance and disease related complications such as, for example, HIV-associated neurocognitive disorders (HAND). HAND is one of the most common manifestations of HIV-1 pathogenesis that causes cognitive impairment and other CNS-related disorders. For treating disorders such as HAND, delivery of therapeutic agents to the CNS remains a major challenge, primarily due to the ineffective transmigration of drugs through the blood-brain barrier (BBB). In recent years, the advent of nanomedicine has stimulated the development of innovative systems for drug delivery. However, clinical success has been limited due to problems associated with biocompatibility, sustainability, and cytotoxicity of the drugs.

FIU inventors have developed pharmaceutical compositions and methods for the delivery of Efavirenz to HIV reservoir organs. The compositions comprise nanodiamond particles that are small enough (less than 10 nm in diameter) to penetrate the tight junctions of the BBB and subsequently migrate to selected treatment areas. The surface of the ND particles can be electrostatically charged, facilitating the adsorption of various therapeutic and/or diagnostic agents having positive or negative charges. Optionally, the surface of the ND particles can be chemically modified with functionalities such as, for example, carboxylic acid, lactone, ketone, ether, hydroxyl, and/or amine. Furthermore, biological molecules such as, for example, amino acids, proteins, cells, hormones, vitamins, DNAs, siRNAs, antibodies, and RNAs, can be adsorbed or covalently attached to the ND particles’ surfaces without altering their biological activities. Finally, the increased drug-loading capacity attributed to ND particles’ large surface area can lead to more sustained drug release profile and improve drug dosing regimens.

  • Targeted nanodrug delivery of anti-HIV drug to the HIV reservoir organs like the brain, lymphoid tissue, bone marrow, genital tract, and gut-associated lymphoid tissue
  • Sustained release of drug
  • Image guided drug delivery
  • Biocompatible and nontoxic to cells
  • Can cross the blood-brain barrier
  • Can adsorb large quantity of drug allowing sustained release of drug over long period of time

Call Anne-Laure “Anlo” Schmitt-Olivier at 305-348-5948 or fill out the quick contact form below.